Finding a way to comprehensively integrate the presence and grade of clinically significant portal hypertension, amount of preserved liver function and extent of hepatectomy into the guidelines for choosing appropriate candidates to hepatectomy remained challenging. This study sheds light on these issues to facilitate precise surgical decisions for clinicians. Independent risk factors associated with grade B/C post-hepatectomy liver failure were identified by stochastic forest algorithm and logistic regression in hepatitis B virus-related hepatocellular carcinoma patients. The artificial neural network model was generated by integrating preoperative pre-ALB, prothrombin time, total bilirubin, AST, indocyanine green retention rate at 15 min, standard future liver remnant volume and clinically significant portal hypertension grade. In addition, stratification of patients into three risk groups emphasized significant distinctions in the risk of grade B/C post-hepatectomy liver failure. The authors' artificial neural network model could provide a reasonable therapeutic option for clinicians to select optimal candidates with clinically significant portal hypertension for hepatectomy and supplement the hepatocellular carcinoma surgical treatment algorithm.

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2021-1297DOI Listing

Publication Analysis

Top Keywords

clinically portal
16
portal hypertension
16
artificial neural
12
neural network
12
network model
12
future liver
8
liver remnant
8
remnant volume
8
grade b/c
8
b/c post-hepatectomy
8

Similar Publications

Background: Elexacaftor-tezacaftor-ivacaftor (ETI) has significantly improved the clinical course of people with cystic fibrosis (pwCF) and eligible CFTR variants. In this study, we prospectively evaluated liver elastography, liver fibrosis indices and liver tests in children with CF aged 6-12 years started on ETI therapy.

Methods: Body mass index, sweat test, percent predicted forced expiratory volume in one second, serum markers of liver injury or portal hypertension, liver fibrosis indices, controlled attenuation parameter and liver stiffness were assessed before starting ETI and three and twelve months post-ETI, according to new international guidelines.

View Article and Find Full Text PDF

Non-Bioartificial Artificial Liver Support System in Acute Liver Failure: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Clin Res Hepatol Gastroenterol

January 2025

Evidence-Based Medicine Center, School of Basic Medical Science, Lanzhou University, 730000, Lanzhou, China; Centre for Evidence-Based Social Science/Center for Health Technology Assessment, School of Public Health, Lanzhou University, 730000, Lanzhou, China; Gansu Key Laboratory of Evidence-Based Medicine, Lanzhou University, 730000, Lanzhou, China. Electronic address:

Background: Acute liver failure (ALF) poses a significant threat to patient health with high mortality rates. While Non-Bioartificial Artificial Liver Support system (NBALSS) has been utilized as a transitional intervention to liver transplant, its efficacy remains uncertain, It is also used as a last-line treatment for patients who are not candidates for liver transplantation.

Objective: The aim of this study was to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of NBALSS in treating acute liver failure (ALF).

View Article and Find Full Text PDF

Objectives: To study the correlation between sarcopenia and hypertrophy of the future liver remnant(FLR) in patients undergoing portal vein embolization(PVE) before liver resection, and to assess the outcomes after resection.

Methods: This retrospective study examined patients underwent PVE from May 2012 to May 2023. Demographic, clinical and laboratory features were documented and total liver volumes(TLV) and FLR volumes were measured before and 2-4 weeks after PVE.

View Article and Find Full Text PDF

Chemotherapy is a potent tool against cancer, but drug resistance remains a major obstacle. To combat this, understanding the molecular mechanisms behind resistance in cancer cells and the protein expression changes driving these mechanisms is crucial. Targeting the Ubiquitin-Proteasome System (UPS) has proven effective in treating multiple myeloma and shows promise for solid tumours.

View Article and Find Full Text PDF

Gut microbiome dysbiosis is not associated with portal vein thrombosis in patients with end-stage liver disease: a cross-sectional study.

J Thromb Haemost

January 2025

University of Groningen, Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, the Netherlands. Electronic address:

Background: Portal vein thrombosis (PVT) is a common complication in patients with end-stage liver disease (ESLD). The portal vein in ESLD patients is proposedly an inflammatory vascular bed due to translocation of endotoxins and cytokines from the gut. We hypothesized that a pro-inflammatory gut microbiome and elevated trimethylamine N-oxide (TMAO), a driver of thrombosis, may contribute to PVT development.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!